Growth

Investing in Infinitus

Scott Kupor Posted October 23, 2024

The US healthcare industry spends at least $82.7B a year on back-office administrative work. In 2022, spending on administrative tasks increased a staggering 50% compared to the previous year. To put it plainly: this is a massive, growing problem for an ecosystem already plagued by significant challenges.

Despite this, a tremendous amount of healthcare data is exchanged via manual phone calls between payors, providers, patients, and pharma companies. Some of these calls are to manage prior authorization of future medical procedures, while others are to manage dispute resolutions between various parties—like who’s going to pay for medical services already delivered. Most of these calls are inefficient, since most parties spend their time waiting on hold instead of serving patients. 

Estimates suggest that every year, billions of these back-office calls take place, and last 20–30 minutes. Such operational inefficiencies may seem run of the mill, but they can cause delays in patient access to treatment and lead to even more expenditures in the future—not to mention increased rates of agent burnout in call centers, which have their own costly downstream impacts to the ecosystem. And according to the most recent CAQH Index, time spent on such administrative work increased 14% on average year over year.

Infinitus is tackling this problem by building the first AI platform specifically designed to automate healthcare phone calls and data gathering. In doing so, the company is meaningfully accelerating patient access to care while mitigating costly employee turnover and improving data capture quality.

The Infinitus AI agent handles phone calls end-to-end on behalf of healthcare providers, fully automating tasks like benefit verification that can last up to an hour for human callers, and updating patient records in real time. Their new proprietary AI copilot, FastTrack, helps front- and back-office staff in every part of healthcare navigate complex, legacy interactive voice response (IVR) systems, and waits on hold on their behalf before gracefully dropping callers into a conversation once a live payor agent is available. Both solutions draw from a vast knowledge graph of payor intelligence gathered from over 4M completed calls. 

Infinitus is also pioneering the safe and accurate use of AI in patient care. Unsurprisingly, healthcare-related phone calls can be lengthy and complex, and the bar for accuracy is exceedingly high. To meet this need, Infinitus has built strict AI guardrails through a coordination layer that sits on top of LLMs and restricts conversations to an approved set of topics while still allowing for bespoke conversational turns and long context windows—a capability even the most modern LLMs have yet to achieve. This makes possible the adoption of AI without fear of hallucinations or bias, a landmark achievement for healthcare.

This is one of the most obvious—yet interesting and computationally complex—use cases for AI in a world where people often ask about the technology’s real-world business applications. What is AI really good for? Parsing unstructured data in lots of disparate documents (in this case, payor policies, formularies, and patient coverage documents) to make it easier for users to answer a simple question, like: will my insurance company reimburse my medical procedure? 

Infinitus is poised to transform how the healthcare ecosystem exchanges information, helping to accurately and efficiently process the massive amount of data that is integral to getting patients high-quality care. 

We first met cofounders Ankit Jain and Shyam Rajagopalan before the company was incorporated, and it’s been inspiring to watch them tackle such a sweeping problem that impacts every single healthcare institution. We are thrilled to have led Infinitus’ Series C and to have joined the board.

Want More a16z Growth?

Deep dives into what makes companies truly great— from the investors and operators at a16z Growth.

Learn More
Recommended For You
Growth

Investing in Talkiatry

Scott Kupor
Bio + Health

Investing in Cedar

Scott Kupor
Bio + Health

Healthtech: Show Your Magic

Jay Rughani, Mehul Mehta, Julie Yoo, and Scott Kupor

Want More Growth?

Deep dives into what makes companies truly great— from the investors and operators at a16z Growth.

Sign Up On Substack

Views expressed in “posts” (including podcasts, videos, and social media) are those of the individual a16z personnel quoted therein and are not the views of a16z Capital Management, L.L.C. (“a16z”) or its respective affiliates. a16z Capital Management is an investment adviser registered with the Securities and Exchange Commission. Registration as an investment adviser does not imply any special skill or training. The posts are not directed to any investors or potential investors, and do not constitute an offer to sell — or a solicitation of an offer to buy — any securities, and may not be used or relied upon in evaluating the merits of any investment.

The contents in here — and available on any associated distribution platforms and any public a16z online social media accounts, platforms, and sites (collectively, “content distribution outlets”) — should not be construed as or relied upon in any manner as investment, legal, tax, or other advice. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment. Any projections, estimates, forecasts, targets, prospects and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Any charts provided here or on a16z content distribution outlets are for informational purposes only, and should not be relied upon when making any investment decision. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, posts may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein. All content speaks only as of the date indicated.

Under no circumstances should any posts or other information provided on this website — or on associated content distribution outlets — be construed as an offer soliciting the purchase or sale of any security or interest in any pooled investment vehicle sponsored, discussed, or mentioned by a16z personnel. Nor should it be construed as an offer to provide investment advisory services; an offer to invest in an a16z-managed pooled investment vehicle will be made separately and only by means of the confidential offering documents of the specific pooled investment vehicles — which should be read in their entirety, and only to those who, among other requirements, meet certain qualifications under federal securities laws. Such investors, defined as accredited investors and qualified purchasers, are generally deemed capable of evaluating the merits and risks of prospective investments and financial matters.

There can be no assurances that a16z’s investment objectives will be achieved or investment strategies will be successful. Any investment in a vehicle managed by a16z involves a high degree of risk including the risk that the entire amount invested is lost. Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by a16z is available here: https://a16z.com/investments/. Past results of a16z’s investments, pooled investment vehicles, or investment strategies are not necessarily indicative of future results. Excluded from this list are investments (and certain publicly traded cryptocurrencies/ digital assets) for which the issuer has not provided permission for a16z to disclose publicly. As for its investments in any cryptocurrency or token project, a16z is acting in its own financial interest, not necessarily in the interests of other token holders. a16z has no special role in any of these projects or power over their management. a16z does not undertake to continue to have any involvement in these projects other than as an investor and token holder, and other token holders should not expect that it will or rely on it to have any particular involvement.

With respect to funds managed by a16z that are registered in Japan, a16z will provide to any member of the Japanese public a copy of such documents as are required to be made publicly available pursuant to Article 63 of the Financial Instruments and Exchange Act of Japan. Please contact compliance@a16z.com to request such documents.

For other site terms of use, please go here. Additional important information about a16z, including our Form ADV Part 2A Brochure, is available at the SEC’s website: http://www.adviserinfo.sec.gov.